[Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases].

Abstract

PURPOSE:

Intravenous immunoglobulins (IVIg) therapy has been reported to be beneficial in a large number of autoantibody-mediated or self-reactive T cells-associated autoimmune diseases. Thus, the beneficial effect of IVIg is probably due to multiple distinct mechanisms.

MAIN POINTS:

The immunoregulatory effect of IVIg in autoimmune diseases is dependent on: interaction of the Fc portion of IVIg with Fc receptors on leucocyte surfaces; interaction of infused IgG with complement components; modulation of synthesis and release of cytokines produced by lymphocytes and monocytes: V region-dependent neutralization of circulating autoantibodies by infused IgG; selection of immune repertoires; modulation of cell proliferation, particularly through modulation of Fas-induced apoptosis; interaction of IVIg with numerous other molecules onto the surface of T and B cells.

PERSPECTIVES:

Better understanding of these mechanisms should allow a better definition of the spectrum of diseases likely to benefit from IVIg treatment.

• Authors: L Mouthon, S Lacroix-Desmazes, A Pashov, S V Kaveri, M D Kazatchkine
• Journal: La Revue de medecine interne (Rev Med Interne) Vol. 20 Suppl 4 Pg. 423s-430s ( 1999) ISSN: 0248-8663 [Print] France
• Vernacular Title: Effets immunomodulateurs des immunoglobulines intraveineuses au cours des maladies auto-immunes.
• PMID: 10522317 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Autoantibodies
• Cytokines
• Immunoglobulins, Intravenous
• Receptors, Fc

Topics

• Apoptosis (drug effects)
• Autoantibodies (drug effects)
• Autoimmune Diseases (immunology, therapy)
• Cytokines (drug effects)
• Humans
• Immunoglobulins, Intravenous (immunology, therapeutic use)
• Lymphocytes (drug effects)
• Monocytes (drug effects)
• Receptors, Fc (drug effects)
• Treatment Outcome